5 Flash Points As FDA Gets Earful On Compounding Guidance
The U.S. Food and Drug Administration's move to dramatically curtail large-scale compounding of lower-cost drugs is stoking fiery debate about benefits for patient safety and possible drug shortages. ...To view the full article, register now.
Already a subscriber? Click here to view full article